08:12 AM EST, 01/06/2025 (MT Newswires) -- CytoMed Therapeutics ( GDTC ) said Monday it has signed a five-year business and research collaboration deal with SunAct Cancer Institute.

The companies plan to explore the efficacy, potency, safety, and tolerability of CytoMed's proprietary allogeneic gamma delta T cells to treat different cancers in human subjects through clinical research, CytoMed said.

The joint effort will include a phase 2 investigator-initiated trial in India that will be jointly sponsored by the two companies, CytoMed said.

CytoMed shares were up over 22% in recent Monday premarket activity.